A clear set of goals is an important step for the future of gene therapy development, but the FDA's going to help some experimental treatments reach patients faster than others. Here's what you need to know about the agency's intentions and some gene-editing stocks that stand to benefit.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,